ANAHEIM, CALIF. (March 27, 1:10 p.m. ET) — Clariant International Inc.'s medical and pharmaceutical segment is refining its future after boosting production capabilities and its Mevopur-brand portfolio.
Over three years, the business applied significant resources to boost efficiency, reduce costs, make the Clariant Masterbatches' medical side “unique in the industry” and eliminate risks for customers, said Carmella Fitzgibbons.
“A substantial amount of money has been invested” enabling production of material for the modified molding or extruding of catheters possibly incorporating elements of tungsten, barium sulfide and radiopaque compounds, Fitzgibbons said during the Medical Design & Manufacturing West trade show, held Feb. 14-16 in Anaheim.
A 15-year Clariant employee, Fitzgibbons was named head of the Holden, Mass.-based North American medical segment of Clariant Masterbatches in late 2011.
“We launched the programs two years ago and put our plants in place,” she said.
Clariant renovated and fully dedicated an existing Lewiston, Maine, masterbatch plant for medical and pharmaceutical production of color concentrates and customized compounds. Previous non-medical work in Lewiston was transferred during 2011 to other Clariant plants.
Clariant masterbatch centers in Jurong, Singapore, and Malm", Sweden, are larger in size than the 35,000-square-foot Lewiston site and had the space to totally segregate production and raw-material flows for medical applications while simultaneously maintaining work on other lines. Clariant needed to deal carefully with the multiple issues relating to the specialized medical business.
Each of the three facilities is certified under ISO 13485:2003 and can accommodate any medical or pharmaceutical requirement under the same guidelines as the other two plants.
Clariant's expanded line of Mevopur-brand masterbatches now can incorporate the MedX silver product series from longtime antimicrobial-agent supplier Sanitized AG of Burgdorf, Switzerland. MedX is useful with polypropylene, polyethylene and polycarbonate applications.
Mevopur antimicrobial options for medical devices can avoid secondary coating operations and the costs of related validation processes. Also, the technology supports manufacturing productivity efforts in the manu- facturing of catheters, endoscopes, surgical instruments and preservative-free pharmaceutical packaging solutions.
The series extends Clariant's antimicrobial options for the medical-device market and facilitates streamlined product development. Depending on the application, Clariant can combine pigments into a masterbatch or maintain transparency levels.
Clariant said next-generation Mevopur nucleants can help reduce cycle times for injection molded devices by up to 12 percent depending on polymer resin grade and, at the same time, improve crystallinity, stiffness and wall thinness.
Clariant has developed data packages to assist customers in their regulatory notifications and filings and adopted “controlled, consistent, compliant” as a tag line for its approach to the medical and pharmaceutical sectors.
The masterbatches business unit formed a global medical and pharmaceutical segment in late 2010. The masterbatch operation is one of 10 business units for Muttenz, Switzerland-based Clariant.